Biosimilarity is not Infringement- Full Stop
On Monday, a DB of the DHC allowed Zydus to manufacture and market a biosimilar of the drug Nivolumab, marketed as Opdivo. The DB order is well-reasoned, providing a clear demarcation between infringement analysis and biosimilarity. Nivolumab, which is at the centre of the controversy, is an anti-cancer medication which increases the ability of the immune system to kill cancer cells.(here) I have previously explain how this drug works here. The EMA website states that Opdivo has “has been shown to benefit patients […]
Biosimilarity is not Infringement- Full Stop Read More »










